Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes

NCT00831779 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

116

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Dapagliflozin
DRUG: Placebo

Sponsor

AstraZeneca

Collaborators

[object Object]